TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02876510
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide infusion
Study: NCT03530917
Drug: RO7020531
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 SAD Cohorts with individual dosages of 40, 100, 140 and 170 mg hard capsules and 3 MAD Cohorts with dosages of 100 and 150mg hard capsules, will be administered orally as per the dosing schedules described above.
Study: NCT03530917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo hard capsules will be administered orally as per the dosing schedules described above.
Study: NCT02166463
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03933319
Drug: pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will be treated with the PLD+trastuzumab regimen until the disease progresses or intolerable toxicity
Study: NCT02166463
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04088604
Drug: LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part2-Dose Escalation and Part2-Dose Extension : subjects take LY01610 with 5-Fu;
Study: NCT02577432
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
Study: NCT02577432
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
Study: NCT05342532
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg twice daily
Study: NCT04380324
Drug: LY3471851
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3471851 drug product is a sterile liquid for SC injection that may be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.
Study: NCT04380324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo dosing solution is 0.9% sodium chloride for injection (USP).
Study: NCT01279590
Drug: PPD10558
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPD10558 40 mg capsule and matching placebo capsule twice a day for 4 weeks, then~PPD10558 80 mg (two 40 mg capsules) twice a day for 8 weeks
Study: NCT01279590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo capsules twice daily for 12 weeks
Study: NCT00652691
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01500343
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gram per day, during 3 months
Study: NCT03344250
Drug: EGFR BATs with TMZ following SOC RT/TMZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care: 6 weeks of RT and TMZ and 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle Experimental: EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ.
Study: NCT03115060
Drug: intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention
Study: NCT03830762
Drug: Xanamem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Xanamem capsules 20mg or 30mg, administered PO once daily. Xanamem is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343.
Study: NCT03830762
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo which is identical in appearance to the test product (20mg, 30mg Xanamem™ QD) except that it contains no active ingredient.
Study: NCT01889862
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug placebo, self-administered daily
Study: NCT03773094
Drug: Guava leaves extract
Normalized name: guava extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural product : The leaves of the guava tree are full of antioxidants, anti-inflammatory agents, antibacterials, and even tannins that can have significant health benefits, from treating stomach troubles to chronic diseases like cancer~•
Study: NCT00846170
Drug: co-biotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: give probiotic 2 t/day
Study: NCT02408354
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a oily liquid, intended for oral (PO) administration. Participants will be given approximately 1g/kg of Placebo divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
Study: NCT00846170
Drug: placebo 2T/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: cross over of patients from study arm to placebo arm
Study: NCT02995694
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol Vaginal Cream
Study: NCT02995694
Drug: Reference
Normalized name: Loreal Preference Dark Auburn 4R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrace Vaginal Cream
Study: NCT00236951
Drug: iron sucrose injection USP
Normalized name: iron sucrose Injection
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03492580
Drug: Anti-hyperglycemic Agents (AHA)
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.
Study: NCT03492580
Drug: Sulfonylureas (SU)
Normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide
Study: NCT02734420
Drug: Toluidine Blue O and PDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
Study: NCT00003950
Drug: CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02606682
Drug: NPT200-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of NPT200-11capsules, orally administered
Study: NCT02606682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of microcrystalline cellulose capsules, orally administered
Study: NCT03763227
Drug: Carbonic Anhydrase Inhibitor (CAI) therapy
Normalized name: Carbonic anhydrase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbonic anhydrase therapy (Oral or Topical) in patients with retinal dystrophy and macular cysts
Study: NCT00706069
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
Study: NCT02295280
Drug: Codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO
Study: NCT01070277
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days
Study: NCT00065065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pill that looks identical to rosiglitazone
Study: NCT00064779
Drug: IL13-PE38QQR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00711074
Drug: AZD5672
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose 200mg aqueous solution
Study: NCT00194675
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 7.5 g daily topical
Study: NCT04618952
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01210287
Drug: nucleoside analog reverse transcriptase inhibitor
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets 100mg qd
Study: NCT01722266
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.~Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards.
Study: NCT04485429
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg subcutaneously every 12 hours (if creatinine clearance greater than 40ml/min) or Unfractionated heparin dosed to target activated partial thromboplastin time (aPTT) between 1.5 - 2.0 times the normal value (if creatinine clearance less or equal to 40ml/min). The treatment period with full-dose heparin will be 7 days. After 7 days of full-dose heparin, patients will continue using prophylactic dose of heparin, according to the standard treatment routine.
Study: NCT00676026
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
Study: NCT03262545
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical properties of placebos are consistent with apatinib
Study: NCT05450575
Drug: Amosartan Q tablet
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine, Losartan, Rosuvastatin
Study: NCT02405858
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.
Study: NCT01837485
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill was applied 3 times a day for 3 months
Study: NCT01815203
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
Study: NCT01815203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo with subsequent cognitive tasks and food test.
Study: NCT00911742
Drug: Zytram
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 Zytram 200 mg tablet as a single dose
Study: NCT04128696
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is available as an intravenous infusion.
Study: NCT04523831
Drug: Ivermectin and Doxycycline
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 6 mg, 2 tab stat and Doxycycline 100 mg twice daily for 5 days
Study: NCT04523831
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated
Study: NCT04166669
Drug: APX001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 Day 1: APX001 500 mg IV BID over a 3-hour infusion; Day 18: APX001 500 mg IV BID over a 3-hour infusion. Cohort 2 Day 1: APX001 1000 mg IV BID over a 3-hour infusion; Day 24: APX001 1000 mg IV BID over a 3-hour infusion.
Study: NCT02196506
Drug: Placebo + ADT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
Study: NCT04502888
Drug: Drug: SL-172154
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Study: NCT02179658
Drug: OPT-80
Normalized name: Glau-Opt
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT04221477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching obinutuzumab will be administered by IV infusion at baseline and Weeks 0, 2, 24, 26, 50 and 52 and subsequently from Week 80 and every 6 months thereafter based on response.
Study: NCT04221477
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
Study: NCT04458051
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Film-coated Tablet Route of administration: Oral
Study: NCT01358877
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as per the schedule specified in the respective arm.
Study: NCT01358877
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered as per the schedule specified in the respective arm.
Study: NCT00102492
Drug: GW679769
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01358877
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as per the schedule specified in the respective arm.
Study: NCT01343628
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5
Study: NCT00420290
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
Study: NCT04472182
Drug: Fluoride varnish with xylitol coated calcium and phosphate
Normalized name: sodium fluoride / xylitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish with xylitol coated calcium and phosphate
Study: NCT01373476
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (4 placebos each time):4#, po, tid,24 weeks.
Study: NCT00543855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast.
Study: NCT00002594
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00553748
Drug: F-18 FLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging. Each imaging dose contains no more than 6.1 micrograms of FLT.
Study: NCT01246986
Drug: LY2157299
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01355523
Drug: Melatonin (N-acetyl-5-methoxytryptamine)
Normalized name: N-Acetyl-5-methoxytryptamine
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 mg oral melatonin daily 1 hour before bedtime
Study: NCT01355523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg oral placebo daily 1 hour before bedtime
Study: NCT04072198
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 every 2 weeks for 8 cycles
Study: NCT04072198
Drug: fluoruracil
Normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3200mg/m2 every 2 weeks for 8 cycles
Study: NCT01653470
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03462030
Drug: Baked non-fat cow's milk powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy with increasing quantities of baked milk.
Study: NCT03462030
Drug: Placebo: Tapioca Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control.
Study: NCT03876288
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
Study: NCT03381196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6).
Study: NCT00071409
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL, once daily, self-administered SC injection for 90 days
Study: NCT01222715
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00562692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion
Study: NCT01860482
Drug: Newrabell® Tablet 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03836729
Drug: GSK3640254
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 will be available as 100 mg capsule. Subjects will be administered GSK3640254 200 mg capsule QD via the oral route.
Study: NCT04317963
Drug: Standard CDI treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CDI treatment includes one or a combination of oral vancomycin, oral vancomycin taper and/or pulse, fidaxomicin, and fidaxomicin taper and/or pulse
Study: NCT00084838
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00084838
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00084838
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00084838
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00084838
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00482287
Drug: MTR105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration, dose escalating (4 arms), single dose
Study: NCT02097537
Drug: Methacholine Chloride (SK-1211)
Normalized name: Methacholine Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00882973
Drug: Genexol-PM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cremophor EL-free polymeric micelle of paclitaxel
Study: NCT01612728
Drug: Women with Arthralgia
Normalized name: Arthricare for Women Moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00773383
Drug: RG1507
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv 9mg/kg weekly
Study: NCT03339635
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to treatment with transdermal placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
Study: NCT04310748
Drug: Total Intravenous Anesthesia(TIVA)
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilation of the patients was provided with a mixture of 40% oxygen and 60% air. Along with induction, propofol at a dose of 6-10 mg/kg/hour and remifentanil infusion at a dose of 0.3-0.4 mcg/kg/min were started for the maintenance of anesthesia. Drug concentrations were adjusted to maintain BIS values between 40-60 in the maintenance of anesthesia.~The MAP target was determined to be in the range of 50-65 mmHg. Blood was collected and stored to measure TAS, TOS, Catalase, Myeloperoxidase, Total Thiol, Native Thiol and Disulfide parameters before and after induction at 5,30,60 and 120 minutes. Hemodynamic data (HR, SBP, DBP, MAP, SpO2) and BIS values of the patients were recorded at 5-minute intervals. The extubation time was recorded. The surgical field opinion and satisfaction assessment were made by Boezaart Scoring and the survey presented to the surgeon, respectively. The patients were followed up for 30 minutes; numerical pain scores and nausea-vomiting scores were recorded